Literature DB >> 15087627

Nerve injury induces a tonic bilateral mu-opioid receptor-mediated inhibitory effect on mechanical allodynia in mice.

Heikki Mansikka1, Chengshui Zhao, Rishi N Sheth, Ichiro Sora, George Uhl, Srinivasa N Raja.   

Abstract

BACKGROUND: Mice lacking the mu-opioid receptor gene have been used to characterize the role of mu-opioid receptors in nociception and the analgesic actions of opioid agonists. In this study, the authors determined the role of mu-opioid receptors in neuropathic pain behaviors and the effectiveness of mu- and kappa-opioid receptor agonists on this behavior in mice.
METHODS: The authors studied the behavioral responses of mu-opioid receptor knockout and wild-type mice to thermal and mechanical stimuli before and after neuropathic pain induced by unilateral ligation and section of the L5 spinal nerve. Response to mechanical stimuli was evaluated by determining the frequency of hind paw withdrawal to repetitive stimulation using a series of von Frey monofilaments. Thermal hyperalgesia was assessed by determining the paw withdrawal latencies to radiant heat and frequency of hind paw withdrawal to cooling stimuli. The effects of systemic morphine, the kappa-opioid agonist U50488H, and naloxone on responses to mechanical and thermal stimuli were also studied in spinal nerve-injured mice.
RESULTS: After spinal nerve injury, wild-type mice developed increased responsiveness to mechanical, heat, and cooling stimuli ipsilateral to nerve injury. mu-Opioid receptor knockout mice not only had more prominent mechanical allodynia in the nerve-injured paw, but also expressed contralateral allodynia to mechanical stimuli. Hyperalgesia to thermal stimuli was similar between mu-opioid knockout and wild-type animals. Morphine decreased mechanical allodynia dose dependently (3-30 mg/kg subcutaneous) in wild-type mice--an effect that was attenuated in the heterozygous mice and absent in the homozygous mu-opioid knockout mice. The kappa-opioid agonist U50488H (3-10 mg/kg subcutaneous) attenuated mechanical allodynia in wild-type, heterozygous, and homozygous mu-opioid mice. Naloxone in wild-type mice resulted in enhanced ipsilateral and contralateral allodynia to mechanical stimuli that resembled the pain behavior observed in mu-opioid receptor knockout mice.
CONCLUSIONS: The authors' observations indicate that (1) unilateral nerve injury induces a bilateral tonic activation of endogenous mu-opioid receptor-mediated inhibition that attenuates mechanical allodynia but not thermal hyperalgesia, (2) both mu- and kappa-opioid agonists attenuate neuropathic pain in mice, and (3) the antihyperalgesic actions of morphine are mediated primarily via mu-opioid receptors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15087627     DOI: 10.1097/00000542-200404000-00022

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  27 in total

1.  TET1 Overexpression Mitigates Neuropathic Pain Through Rescuing the Expression of μ-Opioid Receptor and Kv1.2 in the Primary Sensory Neurons.

Authors:  Qiang Wu; Guihua Wei; Fengtao Ji; Shushan Jia; Shaogen Wu; Xinying Guo; Long He; Zhiqiang Pan; Xuerong Miao; Qingxiang Mao; Yong Yang; Minghui Cao; Yuan-Xiang Tao
Journal:  Neurotherapeutics       Date:  2019-04       Impact factor: 7.620

2.  Nerve injury-induced epigenetic silencing of opioid receptors controlled by DNMT3a in primary afferent neurons.

Authors:  Linlin Sun; Jian-Yuan Zhao; Xiyao Gu; Lingli Liang; Shaogen Wu; Kai Mo; Jian Feng; Weixiang Guo; Jun Zhang; Alex Bekker; Xinyu Zhao; Eric J Nestler; Yuan-Xiang Tao
Journal:  Pain       Date:  2017-06       Impact factor: 6.961

3.  MBD1 Contributes to the Genesis of Acute Pain and Neuropathic Pain by Epigenetic Silencing of Oprm1 and Kcna2 Genes in Primary Sensory Neurons.

Authors:  Kai Mo; Shaogen Wu; Xiyao Gu; Ming Xiong; Weihua Cai; Fidelis E Atianjoh; Emily E Jobe; Xinyu Zhao; Wei-Feng Tu; Yuan-Xiang Tao
Journal:  J Neurosci       Date:  2018-09-28       Impact factor: 6.167

4.  Contribution of the Suppressor of Variegation 3-9 Homolog 1 in Dorsal Root Ganglia and Spinal Cord Dorsal Horn to Nerve Injury-induced Nociceptive Hypersensitivity.

Authors:  Jun Zhang; Lingli Liang; Xuerong Miao; Shaogen Wu; Jing Cao; Bo Tao; Qingxiang Mao; Kai Mo; Ming Xiong; Brianna Marie Lutz; Alex Bekker; Yuan-Xiang Tao
Journal:  Anesthesiology       Date:  2016-10       Impact factor: 7.892

Review 5.  Usefulness of knockout mice to clarify the role of the opioid system in chronic pain.

Authors:  Rafael Maldonado; Josep Eladi Baños; David Cabañero
Journal:  Br J Pharmacol       Date:  2018-01-06       Impact factor: 8.739

6.  Role of lipocalin-2-chemokine axis in the development of neuropathic pain following peripheral nerve injury.

Authors:  Sangmin Jeon; Mithilesh Kumar Jha; Jiyeon Ock; Jungwan Seo; Myungwon Jin; Heejung Cho; Won-Ha Lee; Kyoungho Suk
Journal:  J Biol Chem       Date:  2013-07-08       Impact factor: 5.157

7.  Dynamic temporal and spatial regulation of mu opioid receptor expression in primary afferent neurons following spinal nerve injury.

Authors:  Chun-Yi Lee; Federico M Perez; Wei Wang; Xiaowei Guan; Xiuli Zhao; Janet L Fisher; Yun Guan; Sarah M Sweitzer; Srinivasa N Raja; Yuan-Xiang Tao
Journal:  Eur J Pain       Date:  2011-02-09       Impact factor: 3.931

8.  Mu-opioid receptors are not necessary for nortriptyline treatment of neuropathic allodynia.

Authors:  Yohann Bohren; Dzenan Karavelic; Luc-Henri Tessier; Ipek Yalcin; Claire Gavériaux-Ruff; Brigitte L Kieffer; Marie-José Freund-Mercier; Michel Barrot
Journal:  Eur J Pain       Date:  2009-12-28       Impact factor: 3.931

Review 9.  Spinal inhibitory neurotransmission in neuropathic pain.

Authors:  Bradley K Taylor
Journal:  Curr Pain Headache Rep       Date:  2009-06

10.  Mu-opioid receptor in the nucleus submedius: involvement in opioid-induced inhibition of mirror-image allodynia in a rat model of neuropathic pain.

Authors:  Jun-Yang Wang; Mei Zhao; Fen-Sheng Huang; Jing-Shi Tang; Yu-Kang Yuan
Journal:  Neurochem Res       Date:  2008-05-13       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.